GlassScriptPhysician profile
Denise S Johnson
NPI 1124226147
$7,645.80
in general payments reported to CMS, 2019-2025
25 companies · $1,723 in 2025
The $1,723 reported for 2025 was more than what 91% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $876 · 2022: $1,295 · 2023: $1,800 · 2024: $1,952 · 2025: $1,723.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,475.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,475.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,546.19 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,452.91 | 2021-2025 | Tezspire, Airsupra, Fasenra |
| Glaxosmithkline, LLC. | $912.27 | 2021-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Pfizer INC. | $508.83 | 2021-2025 | |
| Amgen INC. | $452.95 | 2022-2025 | Tezspire |
| Regeneron Healthcare Solutions, INC. | $450.37 | 2021-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $417.46 | 2021-2025 | Cuvitru, Takhzyro |
| Genentech USA, INC. | $384.12 | 2021-2025 | Xolair |
| Novartis Pharmaceuticals Corporation | $297.36 | 2021-2025 | |
| Optinose US, INC. | $251.44 | 2021-2025 | |
| Alk-Abello, INC | $160.23 | 2022-2025 | Odactra, Grastek, Ragwitek |
| Kaleo, INC. | $114.73 | 2021-2024 | Auvi-Q |
| Phadia US INC. | $111.95 | 2021-2022 | |
| Boston Scientific Corporation | $104.05 | 2025 | Enroute Transcarotid Neuroprotection System |
| Leo Pharma INC. | $102.55 | 2022-2024 | Adbry |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $80.19 | 2023-2024 | Prolastin-C Liquid |
| Blueprint Medicines Corporation | $60.82 | 2023-2024 | Ayvakit |
| Aimmune Therapeutics, INC. | $56.19 | 2022 | |
| Uswm, LLC | $38.16 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $33.46 | 2021 | |
| Pharming Healthcare, INC. | $26.41 | 2025 | Ruconest |
| Aytu Biopharma, INC. | $25.74 | 2021 | |
| Ars Pharmaceuticals Operations, INC. | $22.11 | 2025 | Neffy |
| Verona Pharma, INC. | $19.41 | 2025 | Ohtuvayre |
| Merck Sharp & Dohme LLC | $15.90 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Denise Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.